Paraneoplastic Disorders of the Central Nervous System: Update on Diagnostic Criteria and Treatment

ABSTRACT

Although the discovery of antineuronal antibodies has facilitated the diagnosis of paraneoplastic neurological disorders (PNDs), the recognition and treatment of these disorders remain a challenge. Some antineuronal antibodies have a more syndrome-specific association than others, and some syndromes evoke a paraneoplastic etiology more frequently than others. Because antineuronal antibodies may occur in cancer patients without PND, their detection does not necessarily imply that a neurological disorder is paraneoplastic. This review analyzes these issues and suggests a diagnostic strategy based on criteria derived from clinical and immunological findings and the presence or absence of cancer. We provide an update on the clinical features treatment of classic PND of the central nervous system, with the proposal of a general treatment strategy. In addition, we analyze the evidence of a hypothetically effective antitumor immunity in patients with PND, which if confirmed would have implications for treatment of the cancer and PND.

KEYWORDS

Paraneoplastic - neurological - syndromes - antineuronal - antitumor immunity

REFERENCES

• 1 Dalmau J O, Posner J B. Paraneoplastic syndromes affecting the nervous system.  Semin Oncol. 1997;  24 318-328
• 2 Rudnicki S A, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle.  Muscle Nerve. 2000;  23 1800-1818
• 3 Posner J B. Neurologic Complications of Cancer. Philadelphia; F.A. Davis Company 1995:
• 4 O'Neill J H, Murray N M, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases.  Brain. 1988;  111 577-596
• 5 Graus F, Keime-Guibert F, Rene R et al.. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.  Brain. 2001;  124 1138-1148
• 6 Graus F, Bonaventura I, Uchuya M et al.. Indolent anti-Hu-associated paraneoplastic sensory neuropathy.  Neurology. 1994;  44 2258-2261
• 7 Bataller L, Graus F, Saiz A, Vilchez J J. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.  Brain. 2001;  124 437-443
• 8 Gultekin S H, Rosenfeld M R, Voltz R, Eichen J, Posner J B, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.  Brain. 2000;  123 1481-1494
• 9 Dadparvar S, Anderson G S, Bhargava P et al.. Paraneoplastic encephalitis associated with cystic teratoma is detected by fluorodeoxyglucose positron emission tomography with negative magnetic resonance image findings.  Clin Nucl Med. 2003;  28 893-896
• 10 Fakhoury T, Abou-Khalil B, Kessler R M. Limbic encephalitis and hyperactive foci on PET scan.  Seizure. 1999;  8 427-431
• 11 Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre J Y. Limbic encephalitis and small cell lung cancer. Clinical and immunological features.  Brain. 1997;  120 923-928
• 12 Lawn N D, Westmoreland B F, Kiely M J, Lennon V A, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis.  Mayo Clin Proc. 2003;  78 1363-1368
• 13 Rosenfeld M R, Eichen J G, Wade D F, Posner J B, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins.  Ann Neurol. 2001;  50 339-348
• 14 Crotty E, Patz Jr E F. FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer.  J Thorac Imaging. 2001;  16 89-93
• 15 Henson R A, Urich H. Cancer and the Nervous System: The Neurologic Manifestations of Systemic Malignant Disease. London; Blackwell Scientific 1982:
• 16 Bataller L, Wade D F, Graus F, Rosenfeld M R, Dalmau J. The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction.  Ann Neurol. 2003;  53 123-127
• 17 Chan K H, Vernino S, Lennon V A. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity.  Ann Neurol. 2001;  50 301-311
• 18 Vernino S, Lennon V A. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity.  Ann Neurol. 2000;  47 297-305
• 19 Sillevis S P, Kinoshita A, de Leeuw B et al.. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.  N Engl J Med. 2000;  342 21-27
• 20 Scheid R, Honnorat J, Delmont E, Urbach H, Biniek R. A new anti-neuronal antibody in a case of paraneoplastic limbic encephalitis associated with breast cancer.  J Neurol Neurosurg Psychiatry. 2004;  75 338-340
• 21 Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.  J Neurol Neurosurg Psychiatry. 1995;  58 85-87
• 22 Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis.  Ann Neurol. 2003;  54 530-533
• 23 Vernino S, Low P A, Fealey R D, Stewart J D, Farrugia G, Lennon V A. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies.  N Engl J Med. 2000;  343 847-855
• 24 Mason W P, Graus F, Lang B et al.. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.  Brain. 1997;  120 1279-1300
• 25 Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.  J Neurol Neurosurg Psychiatry. 1985;  48 1246-1252
• 26 Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.  Nat Med. 2001;  7 365-368
• 27 Evoli A, Tonali P A, Padua L et al.. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.  Brain. 2003;  126 2304-2311
• 28 Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome.  N Engl J Med. 1990;  322 1555-1560
• 29 Butler M H, Hayashi A, Ohkoshi N et al.. Autoimmunity to gephyrin in Stiff-Man syndrome.  Neuron. 2000;  26 307-312
• 30 Folli F, Solimena M, Cofiell R et al.. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer.  N Engl J Med. 1993;  328 546-551
• 31 Bataller L, Wade D, Graus F, Stacey B S, Rosenfeld M R, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer.  Neurology. 2004;  62 778-782
• 32 Drlicek M, Bianchi G, Bogliun G et al.. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients.  J Neurol. 1997;  244 85-89
• 33 Rees J H, Hain S F, Johnson M R et al.. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders.  Brain. 2001;  124 2223-2231
• 34 Debourdeau P, Gligorov J, Zammit C. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.  N Engl J Med. 1999;  341 1475-1476
• 35 Rojas-Marcos I, Rousseau A, Keime-Guibert F et al.. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer.  Medicine (Baltimore). 2003;  82 216-223
• 36 Graus F, Delattre J Y, Antoine J C et al.. Recommended diagnostic criteria for paraneoplastic neurological syndromes.  J Neurol Neurosurg Psychiatry. 2004;  75 1135-1140
• 37 Koenig H, Patel A. The acute cerebellar syndrome in 5-fluorouracil chemotherapy: a manifestation of fluoroacetate intoxication.  Neurology. 1970;  20 416
• 38 Zawacki T, Friedman J H, Grace J, Shetty N. Cerebellar toxicity of cytosine arabinoside: clinical and neuropsychological signs.  Neurology. 2000;  55 1234
• 39 Engel P A, Grunnet M, Jacobs B. Wernicke-Korsakoff syndrome complicating T-cell lymphoma: unusual or unrecognized?.  South Med J. 1991;  84 253-256
• 40 Peterson K, Rosenblum M K, Kotanides H, Posner J B. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients.  Neurology. 1992;  42 1931-1937
• 41 Bernal F, Shams'ili S, Rojas I et al.. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease.  Neurology. 2003;  60 230-234
• 42 Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer.  Neurology. 2002;  59 764-766
• 43 Voltz R, Gultekin S H, Rosenfeld M R et al.. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.  N Engl J Med. 1999;  340 1788-1795
• 44 Kinirons P, Fulton A, Keoghan M, Brennan P, Farrell M A, Moroney J T. Paraneoplastic limbic encephalitis (PLE) and chorea associated with CRMP-5 neuronal antibody.  Neurology. 2003;  61 1623-1624
• 45 Wainwright M S, Martin P L, Morse R P et al.. Human herpesvirus 6 limbic encephalitis after stem cell transplantation.  Ann Neurol. 2001;  50 612-619
• 46 Baloh R W, DeRossett S E, Cloughesy T F et al.. Novel brainstem syndrome associated with prostate carcinoma.  Neurology. 1993;  43 2591-2596
• 47 Dalmau J, Graus F, Rosenblum M K, Posner J B. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.  Medicine (Baltimore). 1992;  71 59-72
• 48 Yu Z, Kryzer T J, Griesmann G E, Kim K, Benarroch E E, Lennon V A. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.  Ann Neurol. 2001;  49 146-154
• 49 Saiz A, Dalmau J, Butler M H et al.. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma.  J Neurol Neurosurg Psychiatry. 1999;  66 214-217
• 50 Dalmau J, Gultekin S H, Voltz R et al.. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders.  Brain. 1999;  122 27-39
• 51 Horwich M S, Cho L, Porro R S, Posner J B. Subacute sensory neuropathy: a remote effect of carcinoma.  Ann Neurol. 1977;  2 7-19
• 52 Camdessanche J P, Antoine J C, Honnorat J et al.. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients.  Brain. 2002;  125 166-175
• 53 Molinuevo J L, Graus F, Serrano C, Rene R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy.  Ann Neurol. 1998;  44 976-980
• 54 de Seze J, Stojkovic T, Hachulla E et al.. Myelopathy-Sjogren's syndrome association: analysis of clinical and radiological findings and clinical course.  Rev Neurol (Paris). 2001;  157 669-678
• 55 Luque F A, Furneaux H M, Ferziger R et al.. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.  Ann Neurol. 1991;  29 241-251
• 56 Hersh B, Dalmau J, Dangond F, Gultekin S, Geller E, Wen P Y. Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody.  Neurology. 1994;  44 1754-1755
• 57 Bataller L, Rosenfeld M R, Graus F, Vilchez J J, Cheung N K, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome.  Ann Neurol. 2003;  53 347-353
• 58 Rosenfeld M R, Dalmau J. Current therapies for paraneoplastic neurologic syndromes.  Curr Treat Options Neurol. 2003;  5 69-77
• 59 Chalk C H, Murray N M, Newsom-Davis J, O'Neill J H, Spiro S G. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma.  Neurology. 1990;  40 1552-1556
• 60 Rojas I, Graus F, Keime-Guibert F et al.. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.  Neurology. 2000;  55 713-715
• 61 David Y B, Warner E, Levitan M, Sutton D M, Malkin M G, Dalmau J O. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report.  Cancer. 1996;  78 2153-2156
• 62 Vernino S, O'Neill B P, Marks R S, O'Fallon J R, Kimmel D W. Immunomodulatory treatment trial for paraneoplastic neurological disorders.  Neuro-oncol. 2004;  6 55-62
• 63 Graus F, Dalmou J, Rene R et al.. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.  J Clin Oncol. 1997;  15 2866-2872
• 64 Gill S, Murray N, Dalmau J, Thiessen B. Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer.  Can J Neurol Sci. 2003;  30 269-271
• 65 Byrne T, Mason W P, Posner J B, Dalmau J. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis.  J Neurol Neurosurg Psychiatry. 1997;  62 276-278
• 66 Darnell R B, DeAngelis L M. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies.  Lancet. 1993;  341 21-22
• 67 Zaheer W, Friedland M L, Cooper E B et al.. Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy.  Cancer Invest. 1993;  11 306-309
• 68 Albert M L, Darnell J C, Bender A, Francisco L M, Bhardwaj N, Darnell R B. Tumor-specific killer cells in paraneoplastic cerebellar degeneration.  Nat Med. 1998;  4 1321-1324
• 69 Hetzel D J, Stanhope C R, O'Neill B P, Lennon V A. Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume.  Mayo Clin Proc. 1990;  65 1558-1563
• 70 Sillevis S P, Grefkens J, de Leeuw B et al.. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy.  J Neurol. 2002;  249 745-753
• 71 Lucchinetti C F, Kimmel D W, Lennon V A. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies.  Neurology. 1998;  50 652-657
• 72 Kamel E M, Zwahlen D, Wyss M T, Stumpe K D, von Schulthess G K, Steinert H C. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.  J Nucl Med. 2003;  44 1911-1917
• 73 Keime-Guibert F, Graus F, Broet P et al.. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor.  Neurology. 1999;  53 1719-1723
• 74 Dieckmann K P, Skakkebaek N E. Carcinoma in situ of the testis: review of biological and clinical features.  Int J Cancer. 1999;  83 815-822
• 75 Batchelor T T, Platten M, Hochberg F H. Immunoadsorption therapy for paraneoplastic syndromes.  J Neurooncol. 1998;  40 131-136
• 76 Keime-Guibert F, Graus F, Fleury A et al.. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide and methylprednisolone.  J Neurol Neurosurg Psychiatry. 2000;  68 479-482
• 77 Sillevis Smitt P, Gratama J W, Shamsili S, Hooijkaas H. van't Veer M. Rituximab induced depletion of circulating B cells in anti-Hu and anti-Yo associated paraneoplastic neurologic syndromes.  Neurology. 2003;  60(suppl 1) A3
• 78 Albert M L, Austin L M, Darnell R B. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration.  Ann Neurol. 2000;  47 9-17